Skip to main content
Clinical Trials/JPRN-UMIN000021064
JPRN-UMIN000021064
Completed
未知

Efficacy of Tiotropium bromide (Spiriva 2.5 microgram Respimat 60 puffs) for chronic asthmatic cough refractory to intensive therapies - Efficacy of Tiotropium bromide (Spiriva 2.5 microgram Respimat 60 puffs) for chronic asthmatic cough refractory to intensive therapies

agoya City University Dept of Respiratory Medicine, Allergy and Clinical Immunology0 sites58 target enrollmentFebruary 24, 2016
Conditionsasthma

Overview

Phase
未知
Intervention
Not specified
Conditions
asthma
Sponsor
agoya City University Dept of Respiratory Medicine, Allergy and Clinical Immunology
Enrollment
58
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 24, 2016
End Date
March 31, 2020
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
agoya City University Dept of Respiratory Medicine, Allergy and Clinical Immunology

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • If patients meet the following criteria, they are excluded. Patients who have other respiratory disease such as tuberculosis or lung cancer. currently smoke, had smoking history with 10 pack\-years or more, or had quitted smoking within 6 months prior to the enrollment. have already taken anti\-cholinergic agents or xanthin. have already taken some medicines with anti\-cholinergic effects have allergy for anti\-cholinergic agents or xanthin. have benign prostatic hypertrophy with dysuria. have closed\-angle glaucoma. are during pregnancy or lactaion, or have possibility of pregnancy.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 3
The effectiveness of Tiotropium bromide in patients with severe asthma
IRCT20181015041353N1Zahedan University of Medical Sciences60
Active, not recruiting
Not Applicable
Influence of tiotropium bromide (Spiriva ®) plus salbutamol versus salbutamol on the mucin secretion and sputum properties in subjects with a COPD exacerbation-TIBROMUC- - TIBROMUCAnticholinergic bronchodilators, such as ipratropium bromide, may be used in combination with beta adrenergic agonists as SAlbutamol to produce bronchodilation in excess of that achieved by either agent alone.Therefore we will treat both study arms with salbutamol. One group A will receive tiotropium bromide with salbutamol, while the other group B will receive salbutamol.MedDRA version: 8.1Level: LLTClassification code 10010952Term: COPD
EUCTR2006-005819-10-DEPhilipps-University Marburg
Recruiting
Phase 3
Evaluation of therapeutic effect of Tiotropium Bromide in early stages of chronic obstructive pulmonary disease in patients of subspecialty clinics of Isfahan university of medical science in 2018 - 201
IRCT20190524043684N1Esfahan University of Medical Sciences92
Completed
Phase 4
Study to Evaluate the Effects of Tiotropium Bromide on Chronic Obstructive Pulmonary Disease (COPD) During ExerciseCOPD
NCT00412204McMaster University20
Completed
Not Applicable
Efficacy of Tiotropium Bromide Hydrate on human bronchial mucocillially movement using bronchoscopic specimeRespiratory disease requiring bronchoscopy
JPRN-UMIN000011351Respiratory medicine and oncology Gifu Municipal Hospital50